Icahn School of Medicine at Mount Sinai

Kunal Kumar

Andrew F Stewart

Robert Joseph Devita

Peng Wang

Roberto Sanchez

Hui Wang

Avner Schlessinger

Peter Man-Un Ung

Hailing Li

Adolfo Garcia Ocaña

Robert DeVita

Adolfo Garcia-Ocaña

Described herein are compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Kinase inhibitor compounds and compositions and methods of use

Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R, R, X, n, R, Y, Z, R, R, R, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder. 

Growing community of inventors

New York, NY, United States of America

Kunal Kumar